10,095
Total Claims
$2.0M
Drug Cost
1,372
Beneficiaries
$1,484
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
-3%
Cost per patient vs peers
$1,484 vs $1,524 avg
+41%
Brand preference vs peers
19.3% vs 13.7% avg
Brand vs Generic
81% generic
Brand: 1,945 claims · $1.9M
Generic: 8,150 claims · $160K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,055 | $1.1M |
| Rivaroxaban | 277 | $296K |
| Evolocumab | 158 | $169K |
| Sacubitril/Valsartan | 94 | $97K |
| Dronedarone Hcl | 26 | $54K |
| Alirocumab | 46 | $44K |
| Empagliflozin | 41 | $31K |
| Ticagrelor | 17 | $22K |
| Metoprolol Succinate | 788 | $15K |
| Flecainide Acetate | 233 | $12K |
| Dabigatran Etexilate Mesylate | 36 | $8,087 |
| Atorvastatin Calcium | 563 | $7,521 |
| Diltiazem Hcl | 182 | $6,849 |
| Losartan Potassium | 509 | $6,458 |
| Potassium Chloride | 155 | $5,700 |
Prescribing Profile
62
Unique Drugs
$1.5M
Patient Profile
76
Avg Age
53%
Female
1.58
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About